<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05064371</url>
  </required_header>
  <id_info>
    <org_study_id>19140B</org_study_id>
    <nct_id>NCT05064371</nct_id>
  </id_info>
  <brief_title>Long-Term Extension Study With Eptinezumab as Preventive Treatment in Participants With Migraine in Japan</brief_title>
  <official_title>Interventional, Open-label, Fixed-dose, Long-term Extension Study to Evaluate Safety of Eptinezumab as Preventive Treatment in Patients With Migraine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H. Lundbeck A/S</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an open label extension study, which means that the participants from the&#xD;
      Lead-in Study 19140A (NCT04921384) can join this study, if they meet the study Eligibility&#xD;
      Criteria, and continue to receive the study drug eptinezumab. The main goal of this study is&#xD;
      to investigate long-term safety and tolerability of eptinezumab in Japanese migraine&#xD;
      participants.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The total study duration from the Baseline Visit to the Safety Follow-up Visit is&#xD;
      approximately 68 weeks and includes an Open-Label Treatment Period (60 weeks) and a Safety&#xD;
      Follow-up Period (8 weeks).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">September 21, 2021</start_date>
  <completion_date type="Anticipated">June 10, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events (AEs)</measure>
    <time_frame>From Baseline to Week 68</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Number of Monthly Migraine Days</measure>
    <time_frame>Baseline, Week 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response: Number of Participants With ≥50% Reduction From Baseline in Monthly Migraine Days (MMDs)</measure>
    <time_frame>Baseline to Week 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Headache Impact Test (HIT-6) Score</measure>
    <time_frame>Baseline, Week 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Health-Related Quality of Life (EQ-5D-5L) Visual Analogue Scale (VAS) Score</measure>
    <time_frame>Baseline, Week 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Change (PGIC) Score</measure>
    <time_frame>Baseline to Week 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Most Bothersome Symptom (MBS) Score</measure>
    <time_frame>Baseline, Week 60</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>Eptinezumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive eptinezumab 100 milligrams (mg) at the Baseline visit (Week 0) and eptinezumab 100 mg or 300 mg (depending upon the treatment response) at Weeks 12, 24, 36, and 48 by intravenous (IV) infusions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eptinezumab</intervention_name>
    <description>Concentrate for solution for IV infusion</description>
    <arm_group_label>Eptinezumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  The participant has completed the Primary Outcome Visit (Visit 5) of the lead-in Study&#xD;
             19140A immediately prior to enrolment into this study.&#xD;
&#xD;
          -  The participant is indicated for 60-week preventive treatment of chronic migraine with&#xD;
             eptinezumab according to the clinical opinion of the investigator.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  The participant has a serious adverse event (SAE) or a moderate or severe ongoing AE&#xD;
             from the Lead-In study considered a potential safety risk by the investigator.&#xD;
&#xD;
          -  The participant has a clinically relevant change in vital signs or electrocardiogram&#xD;
             (ECG) from the Lead-In study considered a potential safety risk by the investigator.&#xD;
&#xD;
          -  The participant has a disease or takes medication that could, in the investigator's&#xD;
             opinion, interfere with the assessments of safety, tolerability, or efficacy, or&#xD;
             interfere with the conduct or interpretation of the study.&#xD;
&#xD;
        Other inclusion and exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <role>Study Director</role>
    <affiliation>LundbeckClinicalTrials@Lundbeck.com</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>DOI Clinic Internal Medicine</name>
      <address>
        <city>Hiroshima-Shi Naka-Ku</city>
        <state>Hirosima</state>
        <zip>730-0031</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shin Matsudakai Atago Hospital</name>
      <address>
        <city>Kochi</city>
        <state>Kôti</state>
        <zip>780-0051</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo headache clinic</name>
      <address>
        <city>Shibuya-Ku</city>
        <state>Tokyo</state>
        <zip>151-0051</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nagamitsu Clinic</name>
      <address>
        <city>Hofu-Shi</city>
        <state>Yamaguti</state>
        <zip>747-0802</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 22, 2021</study_first_submitted>
  <study_first_submitted_qc>September 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2021</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

